Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigious | ||
Readability |
H.S. sophomore Avg
|
New words:
abstention, abstract, adjacent, American, andErlotinib, announced, announcement, ASCO, AWP, BDR, begun, bortezomib, CDAC, ChemPharm, compliant, concentration, CORRECT, dexamethasone, earnout, ENDEAVOR, erlotinib, feet, HCC, IMiD, immunomodulatory, intangible, leasehold, lessor, main, margin, mCRC, MDL, nature, oversight, PFS, plant, protoCol, purpose, shell, Society, square, Symposium, Tarceva, toAgreement, Velcade, withHepatocellular
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.9 Amendment NO.1 to Executive Change In Control Severance Benefits Agreement
- 10.23 Letter Agreement Between the Company and John Osborn
- 31.1 Certification of CEO As Required by Rule 13A-14(A) or Rule 15D-14(A)
- 31.2 Certification of CFO As Required by Rule 13A-14(A) or Rule 15D-14(A)
- 32.1 Certifications As Required by Rule 13A-14(B) or Rule 15D-14(B)
Related press release
ONYX Pharmaceuticals similar filings
Filing view
External links